Eiger BioPharmaceuticals’ case should be moved, U.S. trustee says

By Sarah Lizee

Olympia, Wash., April 12 – Eiger BioPharmaceuticals, Inc. is facing a motion from Region 6 U.S. trustee Kevin M. Epstein that seeks to move the company’s Chapter 11 bankruptcy case out of the U.S. Bankruptcy Court for the Northern District of Texas or have the case dismissed.

Epstein said none of the debtors are domiciled in Texas, and none of them have their principal place of business or principal assets in the Northern District of Texas.

The U.S. trustee said that because the court has no discretion to retain the cases, it must either immediately transfer venue to a proper district or dismiss the cases.

Epstein said the case should be transferred to the Northern District of California or the District of Delaware.

The Palo Alto, Calif.-based biopharmaceutical company filed bankruptcy on April 1 under Chapter 11 case number 24-80040.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.